In addition to its pharmaceutical milestones, the Company is also
advancing the development of its non-pharmaceutical products. The upcoming
milestone events expected from these programs include:
- Expansion of the commercial distribution of the Company's personal
care topical oilbody products, specifically Hydresia(TM), through
- Pursuit of commercial opportunities for Hydresia(TM) in Europe
- Collection of two milestone payments from Arcadia Biosciences, Inc.,
upon their successful commercial scale-up of GLA-rich safflower oil
- Initiation of pond trials for the Company's shrimp feed additive,
About SemBioSys Genetics Inc. (http://www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated.
These forward-looking st
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved